Colorectal Cancer Screening Guidelines

Primary Screening Recommendations

The U.S. Multi-Society Task Force on Colorectal Cancer recommends colonoscopy every 10 years and annual FIT as first-tier screening options, with the strongest evidence base (strong recommendation, moderate-quality evidence) 1
The American Cancer Society and U.S. Multi-Society Task Force endorse multitarget stool DNA testing every 3 years as an acceptable screening option for average-risk adults aged 45-85 years 2, 3

Colonoscopy uniquely detects and removes precancerous polyps during the same procedure, directly preventing cancer development rather than merely detecting existing disease 4, 2
Colonoscopy achieves the highest sensitivity for detecting advanced adenomas and precancerous lesions of all sizes, which translates to greater mortality reduction 2
A negative colonoscopy provides 10 years of protection, versus 3 years for Cologuard 2
Cologuard has 87% specificity compared to 95% for FIT, resulting in 13-40% false-positive rates that lead to unnecessary colonoscopies 5

The American College of Cardiology is not relevant to this guideline, however the U.S. Multi-Society Task Force on Colorectal Cancer provides a strong recommendation for screening with either colonoscopy every 10 years OR Cologuard every 3 years for average-risk adults aged 45-75 years 2, 3
African Americans should begin screening at age 45 due to higher CRC risk 1
Continue screening based on prior screening history, life expectancy >10 years, and overall health status for individuals aged 76-85 years 2, 3, 1
Discontinue screening regardless of modality chosen for individuals aged 85+ years 2, 3, 1

The most effective real-world approach is sequential offering of screening tests, which achieves similar overall adherence to offering multiple options but results in higher colonoscopy uptake 1
The sequential screening strategy should be: first offer colonoscopy every 10 years, then offer annual FIT, then offer Cologuard every 3 years, and finally offer CT colonography every 5 years or flexible sigmoidoscopy every 5-10 years 1, 5

Cologuard is endorsed by the American Cancer Society, USPSTF, and the U.S. Multi‑Society Task Force as an acceptable screening option every 3 years for average‑risk adults aged 45–85 years. [6][7]8

The USPSTF explicitly excludes blood‑based circulating tumor DNA (ctDNA) tests such as Shield from colorectal cancer screening recommendations because of limited evidence and the availability of other effective tests. 8
The American College of Radiology (2025) does not list serum‑based tests in its appropriateness criteria for colorectal cancer screening, thereby omitting Shield. 9
Consequently, Shield is not included in any major colorectal cancer screening guidelines (American Cancer Society 2018, USPSTF 2021, U.S. Multi‑Society Task Force 2017, ACR 2025) and remains investigational. [6][7][8][9]

Any positive result from a non‑colonoscopy screening test—including Cologuard—requires prompt diagnostic colonoscopy. [6][7]8
Shield should not be offered as a screening option because it lacks guideline endorsement and has no demonstrated mortality benefit. [8][9]
Clinicians should not present Shield as equivalent to Cologuard; only guideline‑endorsed tests (colonoscopy, FIT, Cologuard) should be used for screening. [8][9]

Screening is not recommended for individuals with a life expectancy of less than 10 years or for those older than 85 years, as the potential harms outweigh benefits. [6][7]